Premium
P1‐464: ALZHEIMER'S DISEASE‐ASSOCIATED NEURODEGENERATION IS RELATED TO ABNORMAL BIOMARKER LEVELS OF CEREBROVASCULAR DISEASE AND AMYLOID
Author(s) -
Lao Patrick J.,
Brickman Adam M.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.474
Subject(s) - biomarker , neurodegeneration , hyperintensity , white matter , neuroimaging , atrophy , abnormality , medicine , alzheimer's disease neuroimaging initiative , disease , amyloid (mycology) , alzheimer's disease , pathology , magnetic resonance imaging , cardiology , neuroscience , psychology , radiology , biology , psychiatry , biochemistry
* represents p<0.05 for significantly different prevalence between groups. Background:Accurate and early assessment of the mild cognitive impairment patients progressing to develop full dementia is a very challenging task. Methods:We acquired the multimodal data of structural and functional MRI (sMRI and fMRI) and PET scan based Amyloid-beta labels of 84 subjects in this study to assess the disease progression. We used independent component analysis, correlation analysis and linear mixed effect model to assess and explore the disease specific imaging biomarkers. Results:Analysis of structural MRI revealed obvious cortical degeneration in patients who have amyloid positive PET label. and, analysis of functional MRI with applying the group independent component analysis (ICA) showed that default mode network (DMN) and dorsal attention network (DAN) have statistical significance. Specifically, DMN is different between AD and normal control (p1⁄40.0159). Also, DAN is different between amyloid positive and negative dementia (p1⁄40.011). Age, K-MMSE (normalized with education) also analyzed and showed statistically significant co-relations. Conclusions:We found dementia progression assessment with multimodal imaging biomarker data from sMRI, fMRI. Using these results, we may contribute significantly to help the clinicians in differential diagnosis and progression assessment of dementia.